An Allele of IKZF1 (Ikaros) Conferring Susceptibility to Childhood Acute Lymphoblastic Leukemia Protects Against Type 1 Diabetes
OBJECTIVE IKZF1 encoding Ikaros, an essential regulator of lymphopoiesis and immune homeostasis, has been implicated in the development of childhood acute lymphoblastic leukemia (C-ALL). Because recent genome-wide association (GWA) studies have linked a region of the 3′-UTR of IKZF1 with C-ALL susceptibility, we tested whether IKZF1 is associated with the autoimmune disease type 1 diabetes.
RESEARCH DESIGN AND METHODS rs10272724 (T>C) near IKZF1 at 7p12 was genotyped in 8,333 individuals with type 1 diabetes, 9,947 control subjects, and 3,997 families of European ancestry. Association was tested using logistic regression in the case-control data and by the transmission disequilibrium test in the families. Expression data for IKZF1 by rs10272724 genotype were obtained using quantitative PCR of mRNA/cDNA generated from peripheral blood mononuclear cells from 88 individuals, whereas expression data for five other neighboring genes were obtained from the online Genevar dataset.
RESULTS The minor allele of rs10272724 (C) was found to be protective from type 1 diabetes (odds ratio 0.87 [95% CI 0.83–0.91]; P = 1.1 × 10−11). rs10272724 was not correlated with levels of two transcripts of IKZF1 in peripheral blood mononuclear cells.
CONCLUSIONS The major susceptibility genotype for C-ALL confers protection from type 1 diabetes. Our finding strengthens the link between autoimmunity and lymphoid cancers. Further investigation is warranted for the genetic effect marked by rs10272724, its impact on IKZF1, and the role of Ikaros and other family members, Ailios (IKZF3) and Eos (IKZF4), in autoimmunity.
IKZF1 encodes Ikaros, a zinc-finger transcription factor with a regulatory role in lymphopoiesis and the maintenance of cytokine expression in mature lymphocytes (1,2). Mice with a null mutation in IKZF1 (Ikaros−/−) display complete penetrance of leukemia, increased CD4+ to CD8+ T-cell ratios, and defects in T-cell maturation, including decreased T-cell receptor signaling thresholds during central tolerance (1). Mice heterozygous for the null mutation in IKZF1 (Ikaros+/−) exhibit milder features, but abnormalities including reduced B-cell precursors, a highly increased proliferative response to T-cell receptor engagement, and high rates of T-cell leukemia and lymphomas have been observed (3).
Human studies suggest a specific role for Ikaros in childhood acute lymphoblastic leukemia (C-ALL). Development of C-ALL is linked to somatically acquired mutations that add to inherited cancer susceptibility alleles (4). In 2009, deletions of IKZF1 were reported in 28.6% of C-ALL affected adults (5) and in 83.7% of BCR-ABL1 C-ALL patients examined (6). Combined, the human and murine studies suggest that diminished expression of IKZF1 interrupts lymphocyte development, creating conditions that maintain the rapidly dividing lymphoblasts that characterize ALL.
Two recent genome-wide association (GWA) studies have identified a C-ALL susceptibility locus near IKZF1 (7,8). The identified C-ALL-associated single nucleotide polymorphisms (SNPs), rs4132601 (T>G) and rs11978267 (A>G), as well as two others near IKZF1, rs11980379 (T>C) and rs10272724 (T>C), showed evidence of association with type 1 diabetes in a separate GWA study (P = 2.0 × 10−6, 2.6 × 10−6, 2.5 × 10−6, and 1.4 × 10−6, respectively; www.t1dbase.org), although not at the level the authors required for follow-up (P < 1 × 10−6) (4). All four SNPs are in high linkage disequilibrium (LD, r2>0.98) in the British 1958 Birth Cohort (B1958) controls (http://www.b58cgene.sgul.ac.uk), suggesting they mark the same potential causal variant for type 1 diabetes. Type 1 diabetes is a disease of abnormal immunity, wherein autoimmune destruction of pancreatic β-cells results in a state of insulin dependency (8,9). Type 1 diabetes results from the influence of environmental factors acting on an underlying genetic susceptibility (9). Although no direct link between IKZF1 and type 1 diabetes has been reported, the previously reported, but not highlighted or followed up, association of the chromosome 7p12.2 region containing IKZF1 with type 1 diabetes (10; www.t1dbase.org), the immunologic importance of IKZF1 (11), and the association of IKZF1 with susceptibility to C-ALL (7,8) prompted us to select the SNP most associated with type 1 diabetes, rs1027274 (T>C) (P = 1.4 × 10−6) near IKZF1, for follow-up genotyping to assess association with type 1 diabetes and to determine whether a common genetic component exists for C-ALL and type 1 diabetes.
RESEARCH DESIGN AND METHODS
A total of 8,333 type 1 diabetes cases, 9,947 controls, and 3,997 families were genotyped at rs10272724 using TaqMan (Supplementary Methods). All samples were of white European ancestry. Cases were diagnosed with type 1 diabetes before 17 years of age (mean age at diagnosis = 7.8 years) and were from the Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes and Inflammation Laboratory Genetic Resource Investigating Diabetes study (http://www.childhood-diabetes.org.uk/grid.shtml). Controls were obtained from the British 1958 Birth Cohort (n = 6,899; http://www.cls.ioe.ac.uk/studies.asp?section=000100020003) and the WTCCC UK Blood Service (UKBS) sample collection (n = 3,048) (10,12).
STATA version 10 (StataCorp LP, College Station, TX) was used to perform association analyses (http://www.stata.com). rs10272724 was in Hardy-Weinberg equilibrium in unaffected parents and control subjects (P > 0.05). Case-control data were modeled using logistic regression, with disease status as the outcome variable and counts of the minor allele (coded 0, 1, and 2) as the independent variable, assuming a multiplicative allelic effects model. Geographic region was included as a covariate in the model (Supplementary Methods). Families were analyzed using the transmission disequilibrium test (13) (Supplementary Methods). The interdependency of rs10272724 and rs4948088 in the 7p12 region was examined by stepwise logistic regression.
Peripheral blood mononuclear cell isolation and preparation of DNA and RNA.
Peripheral blood mononuclear cells (PBMCs) were purified from heparinized blood diluted 1:1 in PBS (without Ca2+ and Mg2+, GIBCO, Invitrogen, Carlsbad, CA), and 15 mL aliquots were layered onto 10 mL aliquots of Lympholyte (Cedarlane Laboratories Ltd., Burlington, Ontario) followed by centrifugation at 800g for 20 min at room temperature. The harvested PBMC layer was washed twice with ice-cold PBS and centrifuged at 300g for 10 min at 4°C. Pellets were resuspended in TRIzol (Invitrogen) and stored at −80°C in aliquots of 10 × 107 cells/mL. Total RNA from 1 × 107 PBMCs in TRIzol was prepared using chloroform extraction followed by purification with the RNeasy Mini kit (QIAGEN, Hilden, Germany), according to the manufacturer’s instructions. RNA quality was assessed using an Agilent 2100 Bioanalyser, and concentration was evaluated by Nanodrop (Thermo Scientific, Waltham, MA). First strand DNA synthesis was carried out on 1 μg of RNA using Superscript III RT kit and oligo-dT (Invitrogen).
Quantitative PCR evaluation of IKZF1 expression.
Quantitative (q)PCR primers and probe were designed to two transcripts of IKZF1, herein referred to as “Isoform 1” and “Isoform 2” (Supplementary Methods). Probes were labeled with the fluorochrome FAM and quenched using TAMRA. qPCR assays contained 5 μL of 1:10 dilution of oligo-dT primed cDNA, prepared as described above, in 20 μL assays. Cycle threshold (Ct) values were measured using a 7900HT ABI prism (Applied Biosystems, Carlsbad, CA) and analyzed using SDS v2.1 software (ABI). qPCR reactions were run in triplicate, and the ΔCt for the transcript level qPCRs was calculated using the IKZF1 Isoform 1 or Isoform 2 qPCR Ct value minus the single copy gene β2 microglobulin qPCR Ct value. Expression values were compared via one-way ANOVA using Prism software (GraphPad Software Inc., La Jolla, CA).
mRNA expression of genes near rs10272724.
Correlation between rs10272724 and expression in three types of cell lines (primary fibroblasts, Epstein–Barr virus-immortalized lymphoblastoid cell lines, and phytohemagglutinin-stimulated primary T-cells) derived from umbilical cord samples of 75 newborns of Western European origin via the GenCord project was examined in silico (14) using the publicly available HapMap online GENe Expression VARiation (Genevar) resource (http://www.sanger.ac.uk/resources/software/genevar/). Nine probes that passed quality control assessment (Supplementary Table 1) were evaluated for correlation of mRNA expression with rs10272724 genotype by linear regression using the Genevar 2.0.1 Java tool (15) (Supplementary Methods). A P < 0.0056 significance threshold was used within each cell type based on a Bonferroni correction for testing nine transcripts.
Blood for qPCR experiments was collected from 88 nondiabetic donors (rs10272724: 44 TT, 33 CT, 11 CC) selected from a pregenotyped bioresource and processed within 4 hours (www.cambroidgebioresource.org.uk).
All DNA samples were collected with ethical approval from the National Health Service Cambridgeshire Research Ethics Committee. Written consent was obtained from all individuals.
The minor allele of rs10272724 (T>C) near IKZF1 was protective from type 1 diabetes (odds ratio [OR] 0.87 [95% CI 0.83–0.91], P = 4.8 × 10−9; Table 1, Supplementary Table 2). No evidence of association of rs10272724 with sex or age-at-diagnosis was obtained (P > 0.1). Some samples overlapped with those used in the previous GWA study for type 1 diabetes (10). However, in each of the sample sets used by Barrett et al. (10) and in our unique samples, the effect is in the same direction and the overall significance is increased, suggesting the effect is not solely attributable to the original samples (Table 1). The minor allele of rs10272724 was also protective in the families with type 1 diabetes, i.e., under-transmitted to affected offspring (Table 1; relative risk 0.87 [95% CI 0.81–0.93], P = 7.6 × 10−5). Combined, these results indicate that the minor allele, C, of rs10272724 at 7p12.2 is convincingly associated with a reduced risk of type 1 diabetes (P = 1.1 × 10−11). Barrett et al. (10) reported a replicated association with rs4948088 (C>A) with type 1 diabetes in the 7p12.1 region, 554 kb downstream of IKZF1. However, this SNP, marking a confirmed type 1 diabetes locus (http://www.t1dbase.org/page/Regions), is not in LD with rs10272724 in IKZF1 (D’ = 0.02, r2 = 0.0001), and we found by regression analysis that the two effects were independent as both SNPs improve a model with the other SNP included (P < 5.5 × 10−5).
The relative abundance of two different sets of IKZF1 transcripts in mRNA extracted from PBMCs isolated from 88 nondiabetic individuals was assessed using qPCR to determine the association of rs10272724 alleles with gene expression. No evidence of allele-specific expression was obtained (P > 0.1; Fig. 1). Others have reported a correlation of rs4132601 with IKZF1 expression in Epstein–Barr virus-transformed lymphoblastoid cell lines from the HapMap GENEVAR resource (; P = 0.0017). However, this is likely to be a false effect. The probe originally used (Illumina ID ILMN_1676575) contains two high-frequency SNPs in its target, rs62447207 (G>T) and rs62447208 (C>G) in LD with rs10272724 (r2 = 0.76), rendering it unreliable, as evidenced by the absent IKZF1 probe in the latest Genevar data from the study by Dimas et al. (14). In results from 13 eQTL datasets displayed at http://eqtl.uchicago.edu/cgi-bin/gbrowse/eqtl/, there is no reliable evidence for an IKZF1-associated eQTL. Next, correlation of rs10272724 genotype and expression of nine transcripts from other genes within 1 Mb of rs10272724 in three types of cell lines was tested using the latest Genevar dataset by Dimas et al. (14). No correlation was observed between rs10272724 and expression of any of the five neighboring genes (, Supplementary Fig. 1).
We provide evidence that the minor allele of rs10272724 (C), in near-perfect LD with the minor, C-ALL–susceptible, allele of rs4132601 (G), is protective from type 1 diabetes. Of the nearby genes in the region, IKZF1 appeared to be the most likely candidate causal gene for type 1 diabetes in this region given its causal role in C-ALL and its known role in lymphocyte development. However, our analysis revealed that the previously reported correlation of IKZF1 mRNA expression with rs4132601 may be inaccurate given complications with the probe used in the data accessed by Papaemmanuil et al. (8). Furthermore, an IKZF1 genotype-phenotype correlation at rs10272724 was not confirmed by our qPCR analysis of PBMCs. IKZF1 is now an attractive candidate causal gene in type 1 diabetes, and a functional link between rs10272724 and IKZF1 may yet be elucidated on examining specific isoforms of Ikaros. We note that our qPCR assay evaluated the expression of two transcripts conserved across 10 splice variants of IKZF1, spanning six of the seven identified active and dominant-negative isoforms of the protein. In addition, many allele-specific effects on gene expression are known to be tissue or cell-type specific and may even be restricted to particular phases of development. Another ALL-related gene, AF4/FMR2 family member 3 (AFF3), has been associated with type 1 diabetes (10) (J. Cooper, C.W., and J.A.T., unpublished observations), so our report also confirms a second genetic link between these diseases. AFF3 has been implicated as a susceptibility allele in rheumatoid arthritis (rs10865035 and rs9653422) (16), further highlighting the connection between autoimmunity and lymphoid cancers.
Our finding with IKZF1 marks the third Ikaros family member to be associated with type 1 diabetes, the others being the transcription factors Ailios (IKZF3) on chromosome 17q21.2 and Eos (IKZF4) on chromosome 12q13.2 (10,17), whose targets include BCL-2 and FOXP3, respectively. Ikaros family members interact to coordinate functions of immunologic development and homeostasis (18), so it will be important to explore the effect of these interactions in disease etiology. The more than 30 reported interaction partners of the Ikaros family members (http://www.t1dbase.org) suggest the role of IKZF1 in type 1 diabetes could be subtle and yet far reaching. Interactions with the histone deacetylase and chromodomain-helicase-DNA-binding families of proteins suggest chromosome remodeling events could be involved (11,19). Ikaros interactions with the Notch (18) and STAT (20) protein families also suggest that signaling events that affect T-cell activation and maturation could affect the ultimate development of a diabetogenic, leukemia-protected or nondiabetogenic, leukemia-susceptible T-cell repertoire. Thus, further investigation is warranted to elucidate the phenotypic effect of the genetic feature marked by rs10272724, its impact on IKZF1, and the role of Ikaros in autoimmunity.
This work was funded by the Juvenile Diabetes Research Foundation International (JDRF), the Wellcome Trust, the National Institute for Health Research Cambridge Biomedical Research Centre, the National Science Foundation, and the National Institutes of Health Division of Intramural Research. A.D.-E.S. is a National Institutes of Health Cambridge Health Science Research Scholar and a National Science Foundation Graduate Research Fellow. L.J.D is supported by a Wellcome Trust Intermediate Clinical Fellowship. C.W. is supported by the Wellcome Trust (089989). The Cambridge Institute for Medical Research is in receipt of a Wellcome Trust Strategic Award (079895). The authors thank the U.K. Medical Research Council and Wellcome Trust for funding the collection of DNA for the British 1958 Birth Cohort (MRC Grant G0000934, Wellcome Trust Grant 068545/Z/02). They also acknowledge use of DNA from The U.K. Blood Services collection of Common Controls (UKBS collection), funded by the Wellcome Trust Grant 076113/C/04/Z, the Wellcome Trust/JDRF Grant 061858, and the National Institutes of Health Research of England. The collection was established as part of the Wellcome Trust Case-Control Consortium (funding for the project was provided by the Wellcome Trust under award 076113). This research uses resources provided by the Type 1 Diabetes Genetics Consortium, a collaborative clinical study sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Allergy and Infectious Diseases, National Human Genome Research Institute, National Institute of Child Health and Human Development, and Juvenile Diabetes Research Foundation and supported by U01 DK062418. Funding for the project was provided by the Wellcome Trust under award 076113.
No potential conflicts of interest relevant to this article were reported.
A.D.-E.S., J.M.M.H., L.J.D., and J.A.T. researched data, contributed to discussion, wrote the article, and reviewed and edited the article. C.W. and M.J.L. contributed to discussion, wrote the article, and reviewed and edited the article. D.S., M.M.-A., T.M., and H.S. researched data and reviewed and edited the article.
The authors thank all of the patients, control subjects, and family members for participation and the Human Biological Data Interchange and Diabetes UK for U.S. and U.K. multiplex families, respectively; the Norwegian Study Group (Dag Undlien and Kjersti Ronningen) for Childhood Diabetes for the collection of Norwegian families; Constantin Ionescu-Tirgoviste and Cristian Guja, Institute of Diabetes, Nutrition and Metabolic Diseases, Bucharest for Romanian families; and the Academy of Finland and the JDRF for the Finnish families. DNA samples from the British 1958 Birth Cohort were prepared and provided by S. Ring and W. McArdle, Avon Longitudinal Study of Parents and Children (ALSPAC) Laboratory, University of Bristol; R. Jones, Department of Community Based Medicine, University of Bristol; M. Pembrey, Clinical and Molecular Genetic Unit, Institute of Child Health, London; D. Strachan, Division of Community Health Sciences, St. George’s, University of London; and P. Burton, Department of Health Sciences, University of Leicester. The authors thank David Dunger and Barry Widmer, Department of Paediatrics, University of Cambridge, Addenbrooke’s Hospital, and the British Society for Paediatric Endocrinology and Diabetes for the type 1 diabetes case collection and the Cambridge BioResource for nondiabetic donors. The authors also thank H. Stevens, P. Clarke, G. Coleman, S. Duley, D. Harrison, and S. Hawkins, JDRF/Wellcome Trust Diabetes and Inflammation Laboratory, Cambridge Institute for Medical Research, University of Cambridge, for preparation of DNA samples.
This article contains Supplementary Data online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db10-0446/-/DC1.
- Received April 10, 2010.
- Accepted November 30, 2010.
- © 2011 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.